Core Viewpoint - The domestic high-value medical consumables market is undergoing significant changes due to centralized procurement, with domestic companies expected to capture approximately 70% of the mainstream market in the coming years [1][2]. Group 1: Market Dynamics - The sixth batch of national centralized procurement for high-value medical consumables was announced, with 202 companies and 440 products winning bids, indicating a shift towards domestic brands [1]. - Since the implementation of centralized procurement in 2020, the market share of imported brands, which previously dominated over 90%, has been continuously eroded, leading to significant price reductions in products like coronary stents and drug-coated balloons [1][2]. - The average price of joint bone cement dropped by 83.13% due to centralized procurement, significantly reducing the financial burden on patients [2]. Group 2: Competitive Landscape - Domestic companies face a more severe challenge in the medical device sector compared to pharmaceuticals, as the technological gap between domestic products and imported brands is more pronounced [2]. - The centralized procurement model has created a dual-edged sword for domestic companies, allowing them to gain market access while also compressing profit margins due to intense price competition [2][3]. Group 3: Company Performance - Guichuang Tongqiao has actively embraced centralized procurement, resulting in a compound annual growth rate of 50-60% in performance after its products were included in procurement lists [3]. - The company has successfully maintained a gross margin of 71.6% in 2024, only slightly down from 2023, indicating resilience against price pressures [4]. Group 4: Future Outlook - The market for neuro-interventional consumables is expected to slow down after rapid growth, while the peripheral vascular business is projected to maintain a steady growth rate of around 40% [5]. - The company recognizes the need to enhance product quality and build trust among clinicians to facilitate the adoption of domestic brands [5]. Group 5: International Expansion - The international market for medical devices is significantly larger than the domestic market, making global expansion a necessity for companies like Guichuang Tongqiao [6][8]. - The company has entered into an agreement to acquire a stake in the German medical technology company Optimed, aiming to leverage its established R&D and commercialization platform in Europe [8][9]. - Innovation is deemed essential for gaining recognition in mainstream international markets, with the company focusing on both mergers and innovative product development to enhance its global presence [9].

2026年1月14日，第六批国家组织高值医用耗材集采名单公布，202家企业的440个产品中标，行业专家 预判，国产头部企业将瓜分约七成主流市场。而这正是归创通桥董事长赵中十多年前回国创业时瞄准的 目标：做"高质量且价格可负担"的国产器械。 《每日经济新闻》记者了解到，2020年高值耗材集采落地至今，国产替代进程按下了"加速键"：进口品 牌曾垄断超90%份额的赛道被持续挤占，冠脉支架进入千元时代，药物涂层球囊价格亦普遍降至千元级 别，手术费用大幅下探。2022年开始，外周和神经血管介入高值耗材集采也拉开帷幕，相关产品逐步实 现集采覆盖。正是这些集采，推动国产品牌和产品加快进入医院体系。 "未来三到五年，国产医疗器械市场份额肯定能超过50%。"日前，赵中在接受《每日经济新闻》记者采 访时指出，国产取代进口已是不可逆转的趋势。 身为集采受益者，赵中却对行业有着冷静的判断：国内器械创新看似速度飞快，但真正的原创能力与海 外同行相比依然存在差距，不少"自主知识产权"含金量不足，相比创新药，器械领域的成长与超越仍处 于一个需要长期积累、逐步突破的过程之中，而强劲的创新能力也将成为未来国产医疗器械公司最核心 的竞争优势。 ...

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has successfully removed the "B" mark from its stock code, becoming the first 18A high-value consumable medical device company in Hong Kong to achieve this milestone, indicating its growth and profitability recognition by the capital market [3][4]. Financial Performance - In 2024, Guichuang Tongqiao achieved a revenue of 780 million RMB, representing a year-on-year growth of 48.3% [4][8]. - The net profit for the year surpassed 100 million RMB, marking the company's first annual profit [4][8]. - The gross profit margin was recorded at 71.6%, slightly down from the previous year due to price reductions from centralized procurement and proactive pricing strategies to gain market share [8]. - The net cash flow from operating activities reached 174 million RMB, an increase of 76.83% year-on-year [8]. Product Development and Market Position - The company has continuously invested in R&D, leading to successful bids for core products in multiple provincial and national procurement rounds in 2024 [4]. - Key products include the Tongqiao Silver Snake intracranial support catheter and ZYLOX Penguin iliac vein stent, which have gained significant market traction [4][9]. - Guichuang Tongqiao focuses on peripheral vascular intervention and neurointervention consumables, with leading products in the treatment of lower limb artery occlusive disease and deep vein thrombosis [9]. Industry Landscape - The 18A high-value consumables sector in Hong Kong has become increasingly competitive since the first listing of a medical device company under this category in December 2019 [7]. - Companies like Xianruida Medical and Peijia Medical are also emerging in this space, focusing on differentiated competition in peripheral vascular, neurointervention, and heart valve segments [7][9]. - The market is characterized by rapid technological advancements and commercialization efforts, with several companies achieving profitability and significant revenue growth [7][9]. Company Overview - Established in 2012, Guichuang Tongqiao specializes in the R&D, production, and sales of neurovascular and peripheral vascular intervention medical devices [10]. - The company aims to provide high-quality and affordable treatment solutions for cardiovascular disease patients through innovative medical device products [10]. - As of now, Guichuang Tongqiao has developed a product pipeline of 66 items, with 47 products approved for market release by NMPA, and its marketing network covers over 3,000 hospitals in China [10].